DeciBio

Final Reminder! Join us today at 2 PM PT for Engineering the Future of Cell Therapy: Access, Affordability, and Industrialization — a live webinar hosted by DeciBio Consulting and Cellares. We’ll be diving into the challenges and opportunities shaping the next era of cell therapy, from manufacturing innovations to strategies for scaling access and reducing costs. Don’t miss insights from industry leaders driving this transformation. 📅 Today | 2 PM PT Register here: https://lnkd.in/gNnq-xCa

September 2025 brought new updates in digital health! Read more here:      Disease Management / Digital Therapeutics: University of Melbourne researchers developed Baby Moves VIEW, a smartphone app using AI and video sharing to accelerate early cerebral palsy screening and intervention. Philips launched its next-generation Telemetry Monitor 5500 and platform to reduce alarm fatigue, optimize workflows, and extend cardiac monitoring beyond hospital discharge. Apple introduced Apple Watch Series 11 with new hypertension notifications and a sleep score feature, expanding its role in the consumer health space. Informatics / Healthcare IT Solutions: Lila Sciences is advancing autonomous science with AI-driven “Science Factories” that generate hypotheses, design experiments, and iterate across materials, chemistry, and life sciences. Innovaccer has acquired Story Health to extend its Healthcare Intelligence Cloud into AI-assisted specialty care, enabling continuous patient engagement, improved medication adherence, and reduced hospitalizations. Abridge is partnering with Seattle Children's to deploy its AI-powered ambient clinical intelligence platform systemwide, reducing documentation burden and enhancing pediatric care across inpatient, outpatient, and emergency settings. Women’s Health / Femtech: Samsung Healthcare has partnered with healthcare startup Galeon to integrate AI-powered ultrasound devices with a decentralized, blockchain-based EHR, improving women’s health diagnostics while preserving patient privacy. Visana Health raised $24 million to scale its virtual-first, whole-person women’s health clinic, expanding chronic condition management, AI-driven workflows, and employer partnerships to improve outcomes and reduce costs. Neura Health secured $11.4 million in Series A funding to expand its virtual neurology platform, offering nationwide access to board-certified neurologists, AI-supported workflows, symptom tracking, and memory care, addressing the neurology access gap amongst women and improving patient engagement. Check out the newsletter to learn more about these updates in digital health and informatics: https://lnkd.in/gVg4nd_g Subscribe here to get the next newsletter delivered straight to your inbox: https://lnkd.in/gKQn7_zp These posts were curated by Katie Schneider, Katherine Erickson, and Emily L.. #DigitalHealth #WomensHealth

September 2025 life science deal-making saw a focus on differentiated, next-generation assets to bolster late-stage pipelines. Key observations from recent M&A and collaboration activities: • Novartis led with four high-profile deals in cutting-edge modalities like RNAi and molecular glue degraders, signaling a focus on platforms capable of addressing previously undruggable targets. • Roche entered the competitive metabolic disease (MASH) space, while Genmab secured a bispecific oncology asset, reflecting a broader industry emphasis on precision-targeted therapies. • There's a clear pattern of companies leveraging acquisitions to accelerate clinical momentum and gain a first-mover advantage in emerging therapeutic classes, from covalent protein drugs to advanced gene delivery systems. Venture activity mirrored this strategic intensity: • Investors are backing both platform-enabling technologies and clinical-stage innovation, with notable funding rounds for companies like Odyssey Therapeutics, Treeline Biosciences, and Enveda Biosciences. • Deals supporting novel delivery technologies and next-generation therapeutics highlight a trend toward solving bottlenecks in both modality development and therapeutic reach. Overall, the trend continues that funding is increasingly directed not just toward novel targets, but toward the technologies that will define the next generation of therapies. Check out the newsletter to learn more about these updates: https://lnkd.in/gevVw7Ee Subscribe here to get the next newsletter delivered straight to your inbox: https://lnkd.in/gKQn7_zp These posts were curated by Carl Schoellhammer, Etienne McElfresh, Cassidy Humphreys, Aditi Ghalsasi, and Saloni Patel.

We’re excited to introduce the expert panelists joining our upcoming webinar, Engineering the Future of Cell Therapy: Access, Affordability, and Industrialization. Date: Monday, Oct 20, 2025 Time: 2:00pm - 3:00pm PT Swipe through to meet the leaders driving innovation across the cell therapy ecosystem: • Fabian Gerlinghaus, Co-Founder & CEO, Cellares • Christopher McDonald, Board Member, Cellares & Nucleus RadioPharma • Nelly Viseux, Vice President of Cell Therapies Development, Manufacturing, Supply & Quality, Regeneron • Christian Capitini, M.D., Director, University of Wisconsin Carbone Cancer Center Moderators: • Carl Schoellhammer, Ph.D., Partner at DeciBio Consulting • Rebecca Burnham, PhD, Senior Product Manager at DeciBio Consulting Don’t miss this conversation on how the convergence of manufacturing, automation, and access is shaping the future of cell therapies. Register here: https://lnkd.in/g6DSZfEj

September marked a steady deepening of AI integration across the life sciences and healthcare ecosystem. AI in Drug Discovery Eli Lilly and Company launched TuneLab, a federated learning platform granting biotech partners access to its AI drug discovery models while protecting proprietary data, signaling a more open yet secure approach to collaboration. Absci partnered with Oracle and AMD to scale its generative biologics design workflows through enhanced cloud and GPU infrastructure, aiming to speed molecular design and model training. Meanwhile, XtalPi Inc. and PharmaEngine, Inc. advanced their AI-designed PRMT5 inhibitor into clinical trials — the first compound from their joint program to reach human studies — underscoring how algorithmic discovery is beginning to translate into the clinic. AI in Diagnostics The American Medical Association expanded its 2026 CPT codes to include new reimbursement pathways for AI-based diagnostics and remote monitoring, marking a milestone in formal integration of AI tools into clinical billing. Aidoc earned FDA Breakthrough Device designation for a multi-condition CT analysis platform capable of detecting several acute pathologies in one workflow, while Cigna Healthcare became the latest major payer to cover Cleerly’s AI cardiovascular imaging technology, extending access to over 60 million Americans. AI in Healthcare athenahealth introduced an AI-native version of its EHR platform, embedding predictive insights and automated documentation assistance directly into clinical workflows. The American Medical Association also issued new guidance calling for broad stakeholder oversight and governance post-AI deployment to ensure safety, transparency, and accountability. Finally, Onvida Health and Ambience Healthcare launched ambient AI documentation tools directly within Epic’s system, reflecting how AI is now moving from pilots to embedded infrastructure in day-to-day care. Check out the full newsletter here: https://lnkd.in/gaMpVGVQ Subscribe for more monthly AI updates: https://lnkd.in/gKQn7_zp #AIinHealthcare

The global proteomics tools market is projected to grow ~4% annually, reaching ~$39B by 2030, as highlighted in DeciBio’s newly released Proteomics Tools Report: Research and Clinical Markets (2025-2030). What's driving this growth? • Emerging Technologies: Significant investment in novel platforms fuels high-growth segments, such as spatial proteomics and high-plex affinity assays • Protein Direct Relevance: The direct link between proteins and disease makes for diagnostic opportunities, as well as application across the development pipeline  • Multiomics Integration: Multiomic analysis is now standard in advanced research, with 50+% of next-gen proteomics clinical trials layering proteomic data with other ‘omic’ data, such as genomics or transcriptomics, for deeper biological insight To learn more about the proteomics tools market landscape, competitive dynamics, and future trends: https://lnkd.in/gNETxa8X #ProteomicsTools

MRD / monitoring is rapidly expanding, with growing test volumes, broader reimbursement, and increasing clinical trial activity. Yet, significant challenges and questions remain due to a lack of standardization across the field. What does limit of detection (LoD) really mean, and what thresholds are appropriate? How should analytical and clinical sensitivities be compared across assays? What trade-offs exist between different MRD approaches? In our new white paper, “A Lack of Standardization: Navigating MRD Terminology and Specifications,” Amal Thommil explores these questions and more, offering clear frameworks for interpreting MRD data, evaluating assay performance, and understanding the implications of sensitivity metrics. Alongside a robust discussion of test design and methodology, the paper highlights key use cases, reporting considerations, and an overview of reimbursed MRD / monitoring tests. Download the full white paper here: https://lnkd.in/g_csiau2 #MRD #LiquidBiopsy #Oncology #Diagnostics #PrecisionMedicine #DeciBioInsights

Join DeciBio and Cellares for an engaging discussion with industry leaders to explore the convergence of manufacturing, automation, and access shaping the future of cell therapies. Webinar: Engineering the Future of Cell Therapy — Access, Affordability, and Industrialization This webinar will explore the role of manufacturing and automation in lowering costs and redefining how cell therapies reach patients globally. Through expert-led discussions, participants will gain actionable insights into the evolving ecosystem, the strategic hurdles ahead, and the opportunities to scale breakthrough treatments sustainably and equitably. 🗓️ Date: Monday, Oct 20, 2025 🕐 Time: 2:00pm - 3:00pm PT 🔗 Register here: https://lnkd.in/gd32qU4J Moderators: • Carl Schoellhammer, Ph.D., Partner at DeciBio Consulting • Rebecca Burnham, PhD, Senior Product Manager at DeciBio Consulting Panelists: • Fabian Gerlinghaus, Co-Founder & CEO at Cellares • Christian Capitini, M.D., Director at University of Wisconsin Carbone Cancer Center • Christopher McDonald, Board Member at Cellares and Nucleus RadioPharma • Nelly Viseux, Vice President of Cell Therapies Development, Manufacturing, Supply & Quality at Regeneron Join the conversation for an engaging discussion with industry leaders shaping the next era of cell therapies. #CellTherapy #AdvancedTherapies #Automation #Biomanufacturing #Webinar